Pharmaceuticals · NYSE

TEVATeva Pharmaceutical Industries Ltd

Last close
$44.50 +1.9%
52-week range
$37.00 to $44.56
Market cap
$51.9B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$17.3B
+4% vs FY24
Net income
$1.41B
+186% vs FY24
Free cash flow
$1.15B
+53% vs FY24
Net cash
$1.76B
Cash $3.56B, debt $1.80B

Stock price

+15% since Sep 2026

Valuation vs its own history since 2026

Where each multiple sits today inside its own range since 2026, measured at every quarter end. The thin tick is the median.

P/E, trailing
103x
n/a: Not enough history
Price / sales
3.7x
n/a: Not enough history
EV / EBITDA
21.4x
n/a: Not enough history
Price / free cash flow
42.0x
n/a: Not enough history

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
103x
Earnings yield
1.0%
Price / sales
3.7x
Price / book
6.5x
Price / operating cash flow
29.3x
EV / EBITDA
21.4x
EV / sales
3.7x
Free cash flow yield
2.4%

Profitability

Gross margin
65.8%
Operating margin
10.2%
Net margin
3.6%
Return on equity
6.3%
Return on capital
9.4%

Growth per year

Revenue, 3 years
+5.0%
Revenue, 5 years
+0.7%
Revenue, 9 years
-2.6%
EPS, 3 years
n/aNot meaningful (a loss in the window)

Balance sheet

Cash and investments
$4.08B
Total debt
$4.04B
Net cash
$47.0M
Debt / equity
0.51x
Current ratio
0.95x

Shares and dividend

Shares outstanding
1.17B
Share count, 5 years
+6.2%
Beta, 1 year
n/aNot enough price history
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
n/a

n/a: No dividend

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $4.39B
RevenueNet income
Gross profitLatest quarter $2.44B
EBITDALatest quarter $959M
Margins56 / 16 / 5%
GrossOperatingNet
Earnings per shareLatest quarter $0.20
Cash flowLatest quarter $241M
OperatingCapexFree
Cash vs debtLatest quarter $4.08B
Cash and investmentsTotal debt

Where the revenue comes from

License went from 1% to 4% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

ProductDistribution ServiceLicenseProduct and Service Other
FY22
86%10%
$14.9B
FY23
82%10%
$15.8B
FY24
85%10%
$16.5B
FY25
85%9%
$17.3B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Product$14.6B84.6%+4%
Distribution Service$1.55B9.0%-2%
License$678M3.9%+292%
Product and Service Other$423M2.5%-43%

Pharmaceuticals peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
LLY ELI LILLY & Co $1.36T +46% n/a46.8x15.7x 60th percentile
JNJ Johnson & Johnson $688B +8% n/a43.4x6.9x 90th percentile
MRK Merck & Co., Inc. $364B +5% n/a152x5.4x 98th percentile
PFE Pfizer Inc $165B +1% n/a41.2x2.6x 97th percentile
BMY Bristol Myers Squibb Co $130B +4% n/a14.1x2.6x 13th percentile
TEVA Teva Pharmaceutical Industries Ltd $51.9B -16% 10.2%103x3.7x Not enough history

The company

Sector
Health Care
Industry
Pharmaceuticals
CEO
Richard Francis
Employees
42,535 (as of 2018)
Founded
1901
Headquarters
Tel Aviv
Fiscal year ends
December
Website
teva.co.il

What it does

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about TEVA.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 423 active funds. Crowd level: quiet.

Open the Smart money tab